Aortic root surgery with the CARDIOROOT vascular graft : results of a prospective multicenter post-market surveillance study by G. Tasca et al.
RESEARCH ARTICLE Open Access
Aortic root surgery with the CARDIOROOT
vascular graft: results of a prospective
multicenter post-market surveillance study
Giordano Tasca1* , Jaroslav Lindner2, Laurent Barandon3, Petr Santavy4, Carlo Antona5, Jan Burkert6 and
Amando Gamba1
Abstract
Background: Sparing Aortic Valve procedure requires to reproduction of the geometry of the physiologic anatomy
of the aortic root. Thus, the materials adopted may make a difference. CARDIOROOT is a one-piece collagen-coated
woven vascular graft with pseudo-sinuses, which was designed for use in the treatment of aortic root disease. We
report the results of a prospective, multicenter, observational post-market surveillance study evaluating the safety
and performance of the CARDIOROOT in patients requiring aortic root surgery.
Methods: Patients with aortic root disease suitable for treatment with a vascular graft with pseudo-sinuses
CARDIOROOT graft were eligible for participation. The enrolled patients were assessed intraoperatively, post-
operatively, at discharge and at 1-year. Sites assessed complications at each visit, and recorded any reported
adverse events. The study endpoint was mortality and complications through 1-year post-procedure.
Results: Fifty-two patients were enrolled from 6 European centers. All procedures were technically successful.
Operative mortality was 1.9%: one patient suffered hemorrhagic shock unrelated to the graft 1 day following
surgery. At 1-year follow-up the survival rate was 96.2%, with a late death due to pneumonia 5 months post-
procedure. Eleven serious adverse events occurred in 7 patients, which included cardiac complications (pericardial
effusion, myocardial infarction and ventricular arrhythmia), infection (pericardial infection, deep sternal infection and
superficial sternal infection), vascular disorders, including hemorrhagic shock and pleural effusion requiring drainage.
Nine of the 11 events were deemed procedure-related by the local investigator, and all were deemed unrelated to
the device. There were no reports of graft-related adverse events, infection, occlusion or graft failure.
Conclusions: The results of this 1-year follow-up study showed that the CARDIOROOT vascular graft is safe and
effective for the treatment of aneurysmal aortic root in immediate and mid-term follow-up. However, longer term
follow-up is needed before conclusions can be made on the long-term safety and effectiveness.
Trial registration: ClinicalTrials.gov Identifier: NCT01609270. Registered 31 May 2012.
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Background
Aortic root surgery is one of the most technically de-
manding procedures in cardiac surgery with higher risk
of reoperation for bleeding and hospital mortality com-
pared with a standard isolated aortic valve repair or re-
placement. When the aortic root disease is treated by a
valve sparing technique, achieving a precise relationship
among all the components of the aortic root and to re-
store near normal anatomy and function is imperative,
and the materials used contribute greatly. The sparing
aortic valve procedures have shown to be apt for the
treatment of the aortic root diseases with excellent
long-term results [1]. Although valve sparing procedures
have been documented using completely straight tubular
grafts, the use of a pre-formed graft with the shape of
sinus of Valsalva has shown to allow for improved
reproduction of normal aortic root physiology, and sub-
sequently, physiologic results [2, 3]. Materials used to
construct the prosthetic graft are important in order to
optimize the graft’s performance once implanted. For ex-
ample, construction using the woven technique com-
pared to a knitting technique results in fabric less
porous and less prone to dilate over time [4–6]. The
woven technique consists of interlacing two sets of yarn
(warp and weft) oriented at 90 degrees to one another.
This confers peculiar mechanical properties and features
to the graft. Among these features, there are a surface
smoothness, easy handling, a low water permeability and
suture retention strength [7]. The orthogonal arrange-
ment of the yarn components yields a low radial compli-
ance property. This arrangement results in a graft less
prone to dilate immediately after the operation, as well
as over time, compared with those made by means of
knitted technique [4, 6].
In addition, all prosthetic grafts require a sealant to
stop and minimize bleeding. The presence of a sealant
comprised of collagen has shown superior healing prop-
erties with respect to fibroblasts, and a thinner inner
healing tissue (intimal layer formation) compared with
other sealants [8].
CARDIOROOT (Intervascular SAS, La Ciotat, France)
is one piece-design collagen-coated graft adopted in the
repair or reconstruction of the aortic root. The unique
design of the CARDIOROOT graft mimics the anatomy
of the aortic root, and potentially allows physiologic flow
and leaflets dynamics. This graft is made of woven poly-
ester fabric coated with highly purified form of
cross-linked Type I bovine collagen. The graft is con-
structed in three distinct regions including a Valsalva
bulge, uncrimped with a drop shape, a woven tubular
body above the Valsalva section and an uncrimped mini-
skirt collar underneath the Valsalva bulge. (See Fig. 1).
As a condition of commercial approval (Conformité
Européene mark) for the CARDIOROOT vascular grafts,
Intervascular SAS conducted a post-marketing surveil-
lance registry of the CARDIOROOT vascular grafts in
“real world” usage. This was a prospective, open-label,
single-arm, multicenter, observational registry planned
to enroll at least 50 subjects (Clinicaltrials.gov Reference
Number: NCT01609270). The aim of the current study
was to report the safety and performance of the CAR-
DIOROOT vascular graft.
Methods
Patients
From November 2013 to June 2016, 52 patients (41
males, 79%, mean age 58, range 21 to 79 years) were
treated at 6 study centers in Europe (France, Italy and
Czech Republic). Patients with aortic root disease who
were suitable, according to the local Investigators, to be
treated by a CARDIOROOT vascular graft implantation
were invited to participate in the registry. Patients were
excluded based upon the contraindications as specified
in the CARDIOROOT Instructions for Use, as well as
patients that required consecutive aortic surgery, pa-
tients with extensive coronary artery disease, and pa-
tients who required urgent/emergent surgery. The local
Institutional Ethics Committee approved the study
protocol and patients provided written informed consent
before surgery and inclusion in the registry.
Table 1 shows the main clinical characteristics of the
population. Pre-operative echocardiographic assessment
showed an average left ventricular ejection fraction of
60% ± 10%, aortic valve stenosis presence in 19% of pa-
tients, an aortic valve regurgitation (at least moderate)
Fig. 1 CARDIOROOT Device
Tasca et al. Journal of Cardiothoracic Surgery           (2019) 14:94 Page 2 of 6
present in 19% and a bicuspid aortic valve in 10% of pa-
tients. All patients had an aortic root aneurysm and no pa-
tients had documented aortic dissection or aortic trauma.
Surgical procedure
Surgery was performed per clinician discretion. Opera-
tive approach chosen for all patients was a full conven-
tional sternotomy. Average aortic cross clamp time was
93 ± 34min and cardioplegia was delivered in antero-
grade fashion in 69% of patients, in retrograde in 27% or
both in 4%. Valve surgery was performed (either an aor-
tic valve replacement or leaflet repair) in 35 patients
(67%), while other surgical procedures, other than cor-
onary artery bypass grafting (6%), were performed in
15% of patients. Each patient received one CARDIO-
ROOT vascular graft in the thoracic position. The 3
main CARDIOROOT sizes chosen by investigators were
28, 32 and 34mm, which cover the majority of the sizes
used (see Table 2).
Evaluation and endpoints
Following surgical implantation of the CARDIOROOT
graft, the enrolled patients were assessed intraopera-
tively, post-operatively, at discharge, during readmission
(if applicable), at the 30-day follow-up visit, and at 1 year
for survival status and any complications. Transthoracic
echocardiography data was collected if performed per
standard of care.
The study endpoint was the overall rate of deaths (all
causes) and complications assessed at each visit up to
1-year post CARDIOROOT implant procedure. Partici-
pating sites completed a complications form for each as-
sessment time point and also recorded any reported
adverse events. Centralized monitoring was performed;
source-document verification was limited.
Statistical analysis
No formal sample size calculation was performed; regis-
try sample size was based upon commitment with the
Notified Body at the time of CE mark. Data are pre-
sented with number and percentage for all discrete vari-
ables and as average ± standard deviation for all
continuous variables. Survival analysis was summarized
descriptively by visit, and Kaplan-Meier estimates were
provided. Two-sided confidence intervals (CIs) for the
survival rate were calculated and presented using Green-
wood’s formula. The number and percent of observed
events (death or complication) at 30 days and 1 year
were summarized based on subjects with available data
along with the 95% exact binomial CIs for the percent-
ages. Analysis was done using SAS version 9.4 (SAS In-
stitute, Inc., Cary, NC, USA).
Results
Fifty of the 52 patients completed the registry (i.e., com-
pleted 1-year visit after graft implantation). All proce-
dures were technically successful; no procedures were
abandoned or required re-operation. During the 30 post-
operative days, 1 patient died due to hemorrhagic shock,
yielding an operative survival of 98.1%. Another patient
Table 1 Demographics and pre-operative patient characteristics
Variable Mean ± standard deviation
(SD) or n/m (%)
Demographic variables
Age (years), mean ± SD 58 ± 14
BMI (kg/m2) 26.6 ± 3.4
Gender (male), n/m (%) 41/52 (79)
Pre-operative clinical data
Dyslipidemia, n/m (%) 15/52 (29)
Hypertension, n/m (%) 41/52 (79)
Diabetes, n/m (%) 0/52 (0)
Creatinine (mg/dl), mean ± SD 0.9 ± 0.2
Previous cardiac surgery, n/m (%) 4/52 (8)
New York Health Association, NYHA,
functional status >II, n/m (%)
3/52 (6)
Heart failure, n/m (%) 8/52 (15)
Pre-operative cardiac characteristics
Ejection fraction (%), mean ± SD 60 ± 10
Bicuspid aortic valve, n/m (%) 5/52 (10)
Valve stenosis, n/m (%) 10/52 (19)
Valve regurgitation ≥ II, n/m (%) 10/52 (19)
Table 2 Operative results
Operative variable Mean ± SD or n/m (%)
Cardiopulmonary bypass (min), mean ± SD 120 ± 41
Cross clamp time (min), mean ± SD 93 ± 34
Cardioplegia delivery, n/m (%)
Anterograde 36/52 (69)
Retrograde 14/52 (27)
Both 2/52 (4)
Cardioroot diameter (body diameter)
24 mm, n/m (%) 1/52 (2)
26 mm, n/m (%) 3/52 (6)
28 mm, n/m (%) 15/52 (29)
30 mm, n/m (%) 4/52 (8)
32 mm, n/m (%) 14/52 (27)
34 mm, n/m (%) 15/52 (29)
Valve surgery, n/m (%) 35/52 (67)
Coronary artery bypass grafting, n/m (%) 3/52 (6)
Other cardiac procedure, n/m (%) 8/52 (5)
Tasca et al. Journal of Cardiothoracic Surgery           (2019) 14:94 Page 3 of 6
died at 5 months after the operation due to pneumonia,
bringing the 1-year postoperative survival rate to 96.2%.
A total of 54 complications occurred in 32 patients
throughout the follow-up period; 96% of these occurred
within 30 days of the CARDIOROOT implant surgery.
The most common was atrial fibrillation, reported in 17
patients (33%). Four patients required re-operation due
to bleeding/tamponade (2 acute; 2 late). One patient re-
quired a re-operation for cardiac reasons, with sternot-
omy issues. Two patients suffered from sternal site
infections (one superficial; one deep), and required pack-
ing/irrigation and wound vacuum-assisted closure. One
patient experienced transient paralysis. Two patients re-
ported pneumonia; one within 30 days and one at 5
months post-procedure. One patient experienced an un-
related gastro-intestinal event. Nineteen other complica-
tions were recorded but no details were provided. No
specific adverse events relating to aortic regurgitation
was reported. Transesophageal echocardiography was
performed post-operative and at 1-year as per standard
of care. Post-operatively, 38.5% of subjects had no aortic
insufficiency, 48.1% had trace/trivial aortic insufficiency
and 11.5% had mild aortic insufficiency. At 1 year, only
21/52 subjects (40.4%) had a recorded transthoracic
echocardiography. Six [6] of these subjects had no aortic
insufficiency; 9 had trace/trivial aortic insufficiency. Six
[6] subjects had mild aortic insufficiency and no patients
had moderate to severe aortic insufficiency.
Eleven serious adverse events were reported in 7 pa-
tients. The causes were assessed by the local Investiga-
tors and were deemed unrelated to the CARDIOROOT
device. Nine of the 11 serious adverse events were
deemed procedure-related. See Table 3.
Discussion
The results of this 1-year follow-up study, which in-
volved 52 patients, demonstrate that the CARDIOROOT
vascular graft is effective in the treatment of the aortic
root disease. The early and mid-term results have con-
firmed the safety with no anticipated or unanticipated
events related to the CARDIOROOT device. Longer
term follow-up is required to determine long-term ef-
fectiveness of the CARDIOROOT graft.
This registry also confirms the efficacy, as well as the
versatility of the graft, given its adoption for both the
aortic valve sparing and the Bentall procedure as com-
posite graft.
The unique “drop” shape of the CARDIOROOT graft
mimics the physiologic anatomy sinuses of Valsalva. The
bulge does not stretch when uploaded, making the Val-
salva size more predictable. The shape may permit a
more anatomical reconstruction of the sinuses with two
potential benefits. In the case of the Florida-Sleeve pro-
cedure, where the entire aortic root is spared and
wrapped by the graft [9] (Fig. 2), a more physiologic
leaflet-sinus unit morphology restoration is expected, re-
producing a near normal leaflet-sinus unit morphology
[10]. That may ease the transferred part of the leaflet
stress to the adjacent sinus of Valsalva wall [11] with a
possible benefit on the durability of the procedure.
While in the case of a composite graft, the presence of
such sinus of Valsalva might have a positive impact on
coronary flow dynamics [12], as well as on coronary
stress when compared with the straight graft [13]. The
three distinct regions of the CARDIOROOT facilitate
graft handling and make the size and length of the root
more predictable once uploaded by the blood pressure
at the end of the operation. Maintaining a stable shape
and the size of the aortic root is required to preserve the
Table 3 Serious Adverse Events
Serious Adverse Event Incidence
Cardiac disorder
Cardiac tamponade* 1 (1.9%)
Myocardial infarction* 1 (1.9%)
Pericardial effusion* 1 (1.9%)
Pericardial effusion/ Sternal dehiscence* 1 (1.9%)
Ventricular extrasystoles* 1 (1.9%)
Injury, poisoning and procedural complications
Impaired healing/ Sternal wound healing delay* 1 (1.9%)
Postoperative thoracic procedure complication* 1 (1.9%)
Infections and infestations
Pneumonia 1 (1.9%)
Pericardial infection* 1 (1.9%)
Musculoskeletal and connective tissue disorders
Synovial cyst 1 (1.9%)
Vascular disorders
Hemorrhagic shock (death)* 1 (1.9%)
* Deemed by the investigators to be related to the procedure
Fig. 2 Cardioroot graft adopted in a Florida-Sleeve sparing aortic
valve procedure
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correct size ratio among the different components of the
aortic root and in particular between the annulus and
sinotubular junction. While this may have a favorable
impact on valve or prosthesis function and should prolong
the durability of a sparing aortic valve procedure, in the
case of the composite graft, the stability in aortic root
geometry may be useful in maintaining an optimized valve
prosthesis fluid dynamics performance [14, 15].
While this registry was a multi-center, prospective
registry, there are several limitations to note. The regis-
try employed centralized monitoring and did not include
full source document verification. Specific surgical infor-
mation was not considered during data collection. The
registry follow-up is limited to 1 year; further data for
longer term follow-up is needed. The registry was also
restricted by the nature of the procedures included by
sites to aneurysmal disease and did not address dissec-
tion or other uses of the CARDIOROOT graft.
Conclusions
The results of this registry demonstrated early and
mid-term safety and effectiveness of the CARDIOROOT
vascular grafts for the treatment of aneurysmal aortic root.
The graft is fit for both the aortic sparing valve procedure
and aortic root replacement as a composite graft.
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